Brief: Gensight Biologics Announces Regulatory Authorization For Early Access Treatment With Gs010/Lumevoq In Israel

Gensight Biologics SA

22/12/2025 17:14

Dec 22 (Reuters) - Gensight Biologics SA SIGHT.PA:

GENSIGHT BIOLOGICS ANNOUNCES REGULATORY AUTHORIZATION FOR EARLY ACCESS TREATMENT WITH GS010/LUMEVOQ® IN ISRAEL

GENSIGHT BIOLOGICS SA - BILATERAL INJECTION EXPECTED TO BE PERFORMED IN Q1 2026

GENSIGHT BIOLOGICS-PREPARING TO RESUME TALKS WITH GLOBAL REGULATORY AGENCIES FOR LAUNCH OF PIVOTAL GS010/LUMEVOQ PHASE III STUDY RECOVER IN H2 2026

GENSIGHT BIOLOGICS SA - PURSUING OPPORTUNITIES TO OUT-LICENSE GS010 IN MARKETS OUTSIDE USA AND EUROPE

Source text: ID:nBwc3rzQqa

Further company coverage: SIGHT.PA

 ((Reuters.Briefs@thomsonreuters.com;))